Elicio Therapeutics (ELTX) Stock Forecast, Price Target & Predictions

ELTX Stock Forecast

Elicio Therapeutics stock forecast is as follows: an average price target of $1.50 (represents a -71.21% downside from ELTX’s last price of $5.21) and

ELTX Price Target

Elicio Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 30, 2022	Annabel Samimy	Stifel Nicolaus	$1.50	$1.71	-12.28%	-71.21%

The latest Elicio Therapeutics stock forecast, released on Jun 30, 2022 by Annabel Samimy from Stifel Nicolaus, set a price target of $1.50, which represents a -12.28% decrease from the stock price at the time of the forecast ($1.71), and a -71.21% decrease from ELTX last price ($5.21).

Elicio Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$5.21	$5.21	$5.21
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Elicio Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elicio Therapeutics's last price of $5.21. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Elicio Therapeutics Financial Forecast

Elicio Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	$800.00K	$800.00K	$625.00K	$1.35M	$918.75K	$7.41M	$1.06M	$787.50K	$1.89M	$753.00K
High Forecast	-	-	-	-	-	-	-	$800.00K	$800.00K	$625.00K	$1.35M	$918.75K	$7.41M	$1.06M	$787.50K	$1.89M	$753.00K
Low Forecast	-	-	-	-	-	-	-	$800.00K	$800.00K	$625.00K	$1.35M	$918.75K	$7.41M	$1.06M	$787.50K	$1.89M	$753.00K
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Elicio Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Elicio Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	$-7.78M	-	$-5.47M	-	-	-	-	-	$-6.14M	-
Avg Forecast	-	-	-	-	-	-	-	$-160.00K	$-160.00K	$-111.35K	$-240.51K	$-163.68K	$-1.32M	$-189.29K	$-140.30K	$-336.27K	$-134.15K
High Forecast	-	-	-	-	-	-	-	$-160.00K	$-160.00K	$-111.35K	$-240.51K	$-163.68K	$-1.32M	$-189.29K	$-140.30K	$-336.27K	$-134.15K
Low Forecast	-	-	-	-	-	-	-	$-160.00K	$-160.00K	$-111.35K	$-240.51K	$-163.68K	$-1.32M	$-189.29K	$-140.30K	$-336.27K	$-134.15K
Surprise %	-	-	-	-	-	-	-	48.61%	-	49.09%	-	-	-	-	-	18.26%	-

undefined analysts predict ELTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Elicio Therapeutics's previous annual EBITDA (undefined) of $NaN.

Elicio Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	$-7.56M	-	$-7.20M	-	-	-	-	-	$-6.19M	-
Avg Forecast	$-10.59M	$-10.46M	$-10.32M	$-11.14M	$-11.88M	$-9.92M	$-10.83M	$-77.42M	$-73.34M	$-36.11M	$-52.29M	$-49.09M	$-36.96M	$-81.82M	$-77.58M	$-70.25M	$-149.24M
High Forecast	$-10.59M	$-10.46M	$-10.32M	$-11.14M	$-11.25M	$-9.92M	$-10.83M	$-77.42M	$-73.34M	$-36.11M	$-52.29M	$-49.09M	$-36.96M	$-81.82M	$-77.58M	$-70.25M	$-149.24M
Low Forecast	$-10.59M	$-10.46M	$-10.32M	$-11.14M	$-12.52M	$-9.92M	$-10.83M	$-77.42M	$-73.34M	$-36.11M	$-52.29M	$-49.09M	$-36.96M	$-81.82M	$-77.58M	$-70.25M	$-149.24M
Surprise %	-	-	-	-	-	-	-	0.10%	-	0.20%	-	-	-	-	-	0.09%	-

Elicio Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Elicio Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	$2.83M	-	$1.18M	-	-	-	-	-	$1.64M	-
Avg Forecast	-	-	-	-	-	-	-	$830.45K	$830.45K	$648.79K	$1.40M	$953.72K	$7.69M	$1.10M	$817.47K	$1.96M	$781.66K
High Forecast	-	-	-	-	-	-	-	$830.45K	$830.45K	$648.79K	$1.40M	$953.72K	$7.69M	$1.10M	$817.47K	$1.96M	$781.66K
Low Forecast	-	-	-	-	-	-	-	$830.45K	$830.45K	$648.79K	$1.40M	$953.72K	$7.69M	$1.10M	$817.47K	$1.96M	$781.66K
Surprise %	-	-	-	-	-	-	-	3.41%	-	1.81%	-	-	-	-	-	0.84%	-

Elicio Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ELTX last annual SG&A of $2.83M (Jun 23).

Elicio Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	$-2.44	-	$-22.67	-	-	-	-	-	$-0.59	-
Avg Forecast	$-0.78	$-0.77	$-0.76	$-0.82	$-0.88	$-0.73	$-0.96	$-5.70	$-5.40	$-3.20	$-4.63	$-4.35	$-3.27	$-7.25	$-6.88	$-6.22	$-13.22
High Forecast	$-0.78	$-0.77	$-0.76	$-0.82	$-0.83	$-0.73	$-0.96	$-5.70	$-5.40	$-3.20	$-4.63	$-4.35	$-3.27	$-7.25	$-6.88	$-6.22	$-13.22
Low Forecast	$-0.78	$-0.77	$-0.76	$-0.82	$-0.92	$-0.73	$-0.96	$-5.70	$-5.40	$-3.20	$-4.63	$-4.35	$-3.27	$-7.25	$-6.88	$-6.22	$-13.22
Surprise %	-	-	-	-	-	-	-	0.43%	-	7.08%	-	-	-	-	-	0.09%	-

According to undefined Wall Street analysts, Elicio Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELTX previous annual EPS of $NaN (undefined).

ELTX Forecast FAQ

Will Elicio Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ELTX stock, the company can go down by -71.21% (from the last price of $5.21 to the average price target of $1.5), down by -71.21% based on the highest stock price target, and down by -71.21% based on the lowest stock price target.

Can Elicio Therapeutics stock reach $8?

ELTX's average twelve months analyst stock price target of $1.5 does not support the claim that Elicio Therapeutics can reach $8 in the near future.

What are Elicio Therapeutics's analysts' financial forecasts?

Elicio Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.633M (high $-32.001M, low $-33.265M), average SG&A $0 (high $0, low $0), and average EPS is $-2.565 (high $-2.518, low $-2.612). ELTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.513M (high $-42.513M, low $-42.513M), average SG&A $0 (high $0, low $0), and average EPS is $-3.13 (high $-3.13, low $-3.13).